Recombinantly expressed insulin polypeptides and uses thereof

• US 9,074,015 B2
• Filed: 07/22/2011
• Issued: 07/07/2015
• Est. Priority Date: 07/28/2010
• Status: Active Grant

• Current Assignee: SmartCells, Inc. (Merck & Co., Inc.)
• Original Assignee: SmartCells, Inc. (Merck & Co., Inc.)
• Inventors: Lancaster, Thomas M., Murikipudi, Sylaja, Laleau, Rassol, Zion, Todd C.
• Primary Examiner(s): Ha, Julie
• Assistant Examiner(s): Hellman, Kristina M
• Application Number:
  US13/811,910
• Publication Number:
  US 20130190476A1
• Time in Patent Office: 1,446 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07K 14/62 Insulins

Abstract

The present disclosure provides recombinantly expressed insulin polypeptides that comprise an N-linked glycan motif. The N-linked glycan motif is not present in wild-type insulins and enables the recombinant expression of glycosylated insulin polypeptides (e.g., in yeast cells). Based on results obtained with synthetic glycosylated insulin conjugates we predict that when these recombinant glycosylated insulin polypeptides are administered to a mammal, at least one pharmacokinetic or pharmacodynamic property of the glycosylated insulin polypeptide will be sensitive to serum concentrations of glucose (or an exogenous saccharide such as alpha-methyl mannose). Exemplary insulin polypeptides, polynucleotides encoding these insulin polypeptides, glycosylated insulin polypeptides, pharmaceutical formulations and sustained release formulations are provided in addition to methods of use and preparation.

Claims

1. A recombinantly expressed insulin polypeptide comprising

(a) an A-peptide comprising the amino acid sequence of SEQ ID NO:

18 or 47, and;

(b) a B-peptide comprising the amino acid sequence of SEQ ID NO;

43, 44, 45, or 46,

wherein the insulin polypeptide includes a disulfide bridge between positions 6 and 11 of the A-peptide, a disulfide bridge between position 7 of the A-peptide and position 7 of the B-peptide, and a disulfide bridge between position 20 of the A-peptide and position 19 of the B-peptide, wherein the asparagine (Asn) residue at position 28 of SEQ ID NO;

43, position 28 of SEQ ID NO;

44, position 1 of SEQ ID NO;

45, position 1 and 28 of SEQ ID NO;

46, and position 1 of SEQ ID NO;

47 is conjugated to an N-glycan.

2. The polypeptide of claim 1, wherein the A-peptide and B-peptide are comprised within a contiguous amino acid sequence.

3. The polypeptide of claim 1, wherein the N-linked glycan is a branched trimannose.

4. A pharmaceutical formulation comprising a recombinantly expressed insulin polypeptide comprising

(a) an A-peptide comprising the amino acid sequence of SEQ ID NO:

18 or 47, and;

(b) a B-peptide comprising the amino acid sequence of SEQ ID NO;

43, 44, 45, or 46,

wherein the insulin polypeptide includes a disulfide bridge between positions 6 and 11 of the A-peptide, a disulfide bridge between position 7 of the A-peptide and position 7 of the B-peptide, and a disulfide bridge between position 20 of the A-peptide and position 19 of the B-peptide, wherein the asparagine (Asn) residue at position 28 of SEQ ID NO;

43, position 28 of SEQ ID NO;

44, position 1 of SEQ ID NO;

45, position 1 and 31 of SEQ ID NO;

46, and position 1 of SEQ ID NO;

47 is conjugated to an N-glycan; and

a pharmaceutically acceptable carrier.

5. The pharmaceutical formulation of claim 4, wherein the A-peptide and B-peptide are comprised within a contiguous amino acid sequence.

6. The pharmaceutical formulation of claim 4, wherein the N-linked glycan is a branched trimannose.

7. The pharmaceutical formulation of claim 4, wherein the N-linked glycan is GlcNAc₂Man₅ where GlcNAc is β

-linked N-acetyl glucosamine and Man is mannose.